Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 4/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17022590 | 0.83 | PLA2G2A (0.40) | PLA2G2AKDM4EALDH1A1 | |
| SCHEMBL17022701 | 0.78 | HTR7 (0.56) | HTR7OXER1ALDH1A1 | |
| SCHEMBL7387785 | 0.76 | KMT2A (0.50) | PLA2G2AOXER1ALDH1A1 | |
| SCHEMBL17022485 | 0.74 | GSK3B (0.47) | PLA2G2AOXER1ALDH1A1 | |
| SCHEMBL17022496 | 0.74 | PLA2G2A (0.46) | PLA2G2AOXER1ALDH1A1 | |
| SCHEMBL17022699 | 0.73 | POLB (0.42) | POLBPLA2G2AOXER1 | |
| SCHEMBL17022475 | 0.73 | POLB (0.42) | POLBPLA2G2AOXER1 | |
| SCHEMBL18010369 | 0.73 | HTR7 (0.62) | HTR7 | |
| SCHEMBL17022587 | 0.72 | OXER1 (0.62) | PLA2G2AOXER1ALDH1A1 | |
| SCHEMBL17022581 | 0.72 | PLA2G2A (0.48) | PLA2G2AOXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2910547-B1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | UNIV OKAYAMA (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9512075-B2 | Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug | OKAYAMA UNIVERSITY (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20150291523-A1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-2910547-A1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | Okayama University (JP) | 2015-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291523-A1 | COMPOUND; TAUTOMER AND GEOMETRIC ISOMER THEREOF; SALT OF SAID COMPOUND, TAUTOMER, OR GEOMETRIC ISOMER; METHOD FOR MANUFACTURING SAID COMPOUND, TAUTOMER, ISOMER, OR SALT; ANTIMICROBIAL AGENT; AND ANTI-INFECTIVE DRUG | FURIN, ACE, SHARPIN | POLB 4091/4885HTR7 2789/4885PLA2G2A 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.